A CNS-Active FAAH Inhibitor Altered Morphine Tolerance Where a Peripheral Inhibitor Did Not in Mice
URB597 prevented and reversed morphine tolerance in male and female mice, whereas the peripherally restricted FAAH inhibitor URB937 did not reproduce the effect. Where an intervention acts was central to the experimental comparison.
The target regulates several lipid messengers
FAAH terminates signaling from lipids including anandamide and palmitoylethanolamide. Inhibiting it is different from directly administering THC. The investigators used pharmacological and genetic approaches while monitoring morphine-related responses in a tail-immersion test. This measured antinociceptive adaptation rather than every aspect of pain or opioid dependence.
Central access helped distinguish the interventions
The globally active inhibitor prevented and reversed tolerance, and genetic FAAH deletion produced a similar pattern. The peripheral inhibitor did not. These comparisons support a central contribution in the model, although they do not establish that every difference between the drugs is explained exclusively by their distribution.
Different receptor probes had unequal effects
A CB2 antagonist suppressed URB597's effect, while CB1 and PPAR-alpha antagonists attenuated it. The study also measured spinal lipids and gene transcription. These observations support a network of lipid and receptor involvement rather than a claim that the intervention acts only through anandamide at CB1.
Interpreting the evidence
The findings concern male and female mice under defined morphine regimens. They support a mechanistic distinction between central and peripheral intervention, not a clinical recommendation to combine cannabis with opioids.
Related reading: kinase involvement and direct receptor regulation.
Research reference
Fotio Y; Palese F; Guaman Tipan P; et al. (2020). Inhibition of fatty acid amide hydrolase in the CNS prevents and reverses morphine tolerance in male and female mice. British journal of pharmacology. doi:10.1111/bph.15031. Evidence basis: study abstract.
